{{ variable.name }}
Instruction Manual
Gilteritinib Fumarate
【 Common Name 】 Jiretinib Fumarate Tablets
[Brand Name] ALIGIRITINIB
【 Main ingredients 】 Girotinib...... 40mg.
【 Indications 】
This product is suitable for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have detected FMS like tyrosine kinase 3 (FLT3) mutations.
[Usage and Dosage]
120mg each time, once a day.
Both with and without meals are acceptable. The entire tablet should be taken with water and should not be broken or crushed.
It is recommended to treat for 6 months until the patient no longer experiences clinical benefits or unacceptable toxicity.
[Taboo]
Patients who are allergic to this product.
【 Precautions 】
Reversible posterior encephalopathy syndrome (PRER): Patients who experience PRER should discontinue medication.
Prolong QT interval: Patients with QTcF>500 milliseconds interrupt and reduce dosage; Manage hypokalemia or hypomagnesemia before and during administration.
Pancreatitis: Discontinue and reduce the dosage for patients with pancreatitis.
Embryo fetal toxicity: When administered to pregnant women, it can cause harm to the fetus; Stop breastfeeding within two months after administration during lactation.
Adverse reactions include thrombocytopenia, neutropenia, anemia, dizziness, headache, cough, nausea, taste disorders, prolonged QT interval on electrocardiogram, and elevated alanine aminotransferase.
[Appearance] Light yellow tablet.
【 Validity Period 】 4 years from the date of production.
【 Packaging 】 90 tablets/bottle.
[Storage]
Sealed, away from light and moisture, stored at a temperature between 20 ℃ and 25 ℃, and allowed to be offset between 15 ℃ and 30 ℃.
Please keep out of reach of children.
[Production Enterprise]
Laos Alliance Pharmaceutical Group Factory